Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Niemann-Pick Disease Type C stories

Nov 18, 2026

FDA approves adrabetadex for Niemann-Pick disease type C

The FDA approved adrabetadex for Niemann-Pick disease type C, a rare fatal genetic disorder, after treated patients showed longer survival compared to external controls.

Nov 18, 2026·2 sources
00

Top claims

  • ▪Prescribing information for adrabetadex carries warnings for ataxia and fatigue, alongside a boxed warning for hearing impairment including permanent hearing loss requiring baseline and regular hearing evaluations
  • ▪Niemann-Pick disease type C is a rare inherited lysosomal storage disorder affecting roughly one in 150,000 people that impairs the body's ability to transport and metabolize intracellular cholesterol and other lipids
  • ▪The most common adverse events reported in 25% or more of patients taking adrabetadex include hearing impairment, ataxia, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough

Topics

Drug safetyDrug Policy, Pricing & ApprovalGenetic disordersNeurodegenerative diseaseRare diseasesFDA drug approvalIntrathecalOrphan drug designation

Related entities

United States